Improving Healthcare Delivery in Immuno-Oncology
Quality Improvement Initiative
Quality Improvement Initiative

Improving Healthcare Delivery in Immuno-Oncology

A Global Quality Improvement Initiative

Not a member of My prIME? Join now for instant access.

Explore tools and strategies in quality improvement (QI) with this online activity series produced in collaboration with RealCME.

Over the course of several months, you will be able to participate in a QI initiative with a virtual healthcare system to improve the quality of care for patients eligible to receive immune checkpoint inhibitors. This initiative will include 3 CME-certified educational modules, released consecutively over several months, and collaborative telephone calls with our expert faculty to be held after the second and third modules are released.

Join in for the virtual activities and you’ll have the opportunity to take part in the collaborative telephone calls with expert faculty. Don’t miss out on this opportunity!
CME

CME

1.5 AMA PRA Category 1 Credits

Release Date

Release Date

Apr 26, 2018

Expiration Date

Apr 26, 2019

Module 1

  • Immuno-oncology (IO) treatment options
  • Quality improvement in IO
  • Biomarkers in IO
  • Immune-related adverse events
  • Shared decision making

Module 2

  • Coming in August.

Module 3

  • Coming in November.

CURRICULUM CHAIRS

  • Joseph Jacobson, MDChief Quality Officer
    Dana Farber Cancer Institute
    Boston, Massachusetts, United States
  • Timothy Gilligan, MDCo-Director of the Excellence in Healthcare Communication
    Cleveland Clinic
    Cleveland, Ohio, United States
  • John B. A. G. Haanen, MD, PhDProfessor of Translational Immunotherapy of Cancer
    University of Leiden
    Netherlands Cancer Institute
    Amsterdam, the Netherlands

The target audience for this initiative is physicians, physician assistants, nurse practitioners, registered nurses, and other healthcare providers who provide care for patients with cancer in North America and the European Union, including Switzerland and Israel.

Please replace the placeholder with these:
  • Develop optimum treatment strategies using checkpoint inhibitors to treat a variety of tumor types
  • Create approaches to monitor and manage immune-related adverse events (irAEs) resulting from treatment with immune checkpoint inhibitors
  • Discuss best practices related to shared decision making in clinical practice
  • Describe foundational principles of quality improvement as they relate to healthcare
  • Coming in August.

These activities are supported by educational grants from Bristol-Myers Squibb, EMD Serono, and Pfizer.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Improving Healthcare Delivery in Immuno-Oncology - prIME Oncology

prIME Oncology designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

These activities are provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s and RealCME’s databases. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

The posttest is available within the activity.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Gilligan has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Haanen has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Jacobson has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.